<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43587">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956825</url>
  </required_header>
  <id_info>
    <org_study_id>MMC13023-13CTIL</org_study_id>
    <nct_id>NCT01956825</nct_id>
  </id_info>
  <brief_title>The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver</brief_title>
  <official_title>THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <authority>Israel: Clalit Health Services</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the dual therapy of the     amino acid
      L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with
      non alcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the dual therapy of the     amino acid
      L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with
      non alcoholic fatty liver disease.

      the study is an interventional one in which 60 patients who by definition have non alcoholic
      fatty licer disease (NAFLD) are divided randomly (double blind) into 2 groups: group 1:
      &quot;study group&quot;. receive a product (flavoured water) which contains L-CARNITINE an magnesium.
      group 2: control. receive placebo. regular water. Length of trial - 12 weeks. The patients
      will be followed on a weekly base and variuos parameters will be compared (weight, lipid
      profile, insulin resistance etc.).

      &quot;fibrotest&quot; will be used at the beginning of the trial and at the end (week 12) comparing
      the fat content before and after the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>effect of LCARNITINE and magnesium treatment on the liver fat content</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of L-CARNITINE and magnesium treatment on the metabolic panel</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hepatic enzyme profile, lipid profile, weight, inflammatory markers, insulin resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>just water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-CARNITINE AND MAGNESIUM (&quot;slim water&quot; product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm will receive a product &quot;slim water&quot;, which contains 150 mg magnesium lactate and  2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>&quot;slim water&quot;</intervention_name>
    <arm_group_label>L-CARNITINE AND MAGNESIUM (&quot;slim water&quot; product)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        age&gt;18, &lt;80 y evidence to non alcoholic fatty liver disease

        Exclusion Criteria:

        age&lt;18, &gt;80 y pregnancy renal failure congestive heart failure active malignancy liver
        disease - etiology other than non alcoholic fatty liver disease (NAFLD).
        hypothyroidism/cushing total prenteral nutrition (TPN) in the last 6 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DAN FELDMAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DAN FELDMAN, MD</last_name>
    <phone>0522794025</phone>
    <email>danifel100@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YONA KITAY, MD</last_name>
    <phone>09-7471560</phone>
    <email>yonaki@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meir Hospital</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAN FELDMAN, MD</last_name>
      <phone>0522794025</phone>
      <email>danifel100@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>YONA KITAY, MD</last_name>
      <phone>09-7471560</phone>
      <email>yonaki@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non alcoholic fatty liver disease</keyword>
  <keyword>LCARNITINE amino acid</keyword>
  <keyword>magnesium</keyword>
  <keyword>fat content</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carnitine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
